Deep search
Search
Copilot
Images
Videos
Maps
News
Shopping
More
Flights
Travel
Hotels
Real Estate
Notebook
Top stories
Sports
U.S.
Local
World
Science
Technology
Entertainment
Business
More
Politics
Any time
Past hour
Past 24 hours
Past 7 days
Past 30 days
Best match
Most recent
Ozempic 3.0? This drug causes the greatest weight loss — by far
Researchers from Canada reviewed the results of 26 trials to determine which of the weight loss jabs are the most effective for obese adults who do not have diabetes.
Weight-loss drugs like Ozempic may be up for Medicare price negotiations — will Trump support it?
Medicare’s drug pricing negotiations — the first of their kind in the United States, passed under President Joe Biden — face an uncertain future in the incoming Trump administration.
Hello Healthy: A New Year, New Options for Weight Loss and Better Health
Dignity Health January marks Healthy Weight Awareness Month, and with the new year, many are setting health and weight loss goals. As part of this, medical treatments are being
As demand for weight-loss drugs rises, states grapple with Medicaid coverage
Over her three-decade career, weight management physician Dr. Sarah Ro has seen hundreds of patients. Many of them are on Medicaid and have become yo-yo dieters who, despite their best efforts at changing their eating habits and lifestyles,
Ozempic: Beyond Diabetes, A Breakthrough for Weight Loss?
None
Health Matters: GLP-1 drugs work for weight loss, study finds
McGill University researchers say their study has found GLP-1 drugs are safe and effective for treating obesity and overweight adults without diabetes. The authors say the findings support using the medication to treat those who are overweight and obese among otherwise healthy patients.
FDA issues draft guidance on developing weight loss drugs
The U.S. FDA has released a new draft guidance for drugmakers to aid them in developing new treatments for obesity. The new document replaces an earlier draft guidance issued in February 2007. The new guidance stated that its focus is on the design of clinical trials and endpoints to demonstrate sustained weight loss,
Should Medicaid Pay for Ozempic and Other Weight-Loss Drugs?
With 13 states offering coverage, it’s already a $3.9 billion cost. Some state officials say reducing obesity will save programs money in the long run.
3h
on MSN
Semaglutide currently not cost-effective for heart patients without diabetes, study finds
For overweight or obese individuals without diabetes, but with pre-existing cardiovascular disease, semaglutide (Ozempic, ...
DMR News (English) on MSN
1h
Hims & Hers Makes Waves: $1 Million Donation Tied to GLP-1 Support
In a notable move, Hims & Hers Health donated $1 million to President-elect Donald Trump’s inauguration fund, signaling its ...
News Medical on MSN
5h
Statistical model analyzes the cost-effectiveness of semaglutide for non-diabetic obese individuals
For overweight or obese individuals without diabetes, but with pre-existing cardiovascular disease, semaglutide (Ozempic, Wegovy) is not cost-effective at current pricing, new research shows.
13h
Fast Drug Launch For Madrigal Pharmaceuticals Brings Buyout Discussion
Madrigal Pharmaceuticals' strong launch is confirmed with impressive sales in Q1 and Q2. Learn why MDGL stock could benefit ...
STAT
5h
Trump faces an ACA subsidy conundrum
This is the web edition of D.C. Diagnosis, STAT’s twice-weekly newsletter about the politics and policy of health and ...
13d
on MSN
A woman who lost 100 pounds on semaglutide shared 3 ways the holiday season has changed — including not feeling the need to diet in the new year
At her Thanksgiving table in 2024, half of Ashley Dunham's guests were on a GLP-1 weight loss drug. She made green beans for ...
Fierce Healthcare
1d
Found introducing oral dissolvable GLP-1 tablet at reduced price
Weight management platform Found is today launching oral semaglutide dissolvable tablets for individuals looking for ...
2d
Biomea Fusion Reports New Preclinical Data on Icovamenib-Semaglutide Combination Study
New in vivo preclinical data announced today, demonstrate that icovamenib, in combination with semaglutide showed additional 11.5% body weight ...
3d
Ask a health professional: How do semaglutide and tirzepatide support wellness goals?
Ready to crush your New Year’s health goals? These breakthrough medications offer more than weight loss—they support your ...
Hosted on MSN
7h
NVO Stock Up 3% as UBS Upgrades Company Rating From Neutral to Buy
Shares of Novo Nordisk NVO gained 2.8% on Wednesday likely because the analysts at UBS upgraded the company’s rating from ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback